120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
哥伦比亚分枝杆菌感染的临床特征和耐药谱：22例研究
Authors Mei L , Liang F, Liu S , Chen H
Received 13 October 2025
Accepted for publication 16 January 2026
Published 29 January 2026 Volume 2026:19 572058
DOI https://doi.org/10.2147/IDR.S572058
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Hazrat Bilal
Lin Mei,1,2,* Feng Liang,1,* Shengsheng Liu,2 Hua Chen1
1Guangzhou Chest Hospital, Guangzhou, People’s Republic of China; 2Department of Tuberculosis, Anhui Chest Hospital, Hefei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hua Chen, Guangzhou Chest Hospital, No. 62 Hengzhigang Road, Guangzhou, People’s Republic of China, Tel +86-13570550192, Fax +86- 02083595977, Email chenhua1805@163.com
Purpose: Mycobacterium colombiense, a rare yet clinically significant species within the Mycobacterium avium complex, demonstrates a marked propensity for disseminated disease and is associated with high mortality. However, data on its clinical characteristics and drug resistance profiles remain scarce. This study aims to conduct an in-depth analysis of the clinical characteristics and drug resistance profile of Mycobacterium colombiense disease, providing insights for optimizing its diagnosis and treatment strategies.
Patients and Methods: We retrospectively analyzed the clinical data of 22 HIV-negative patients diagnosed with Mycobacterium colombiense disease at Guangzhou Chest Hospital from April 2021 to April 2024. Data included clinical manifestations, laboratory findings, and treatment regimens.
Results: Among the 22 confirmed cases, disseminated Mycobacterium colombiense disease accounted for 63.6% (14/22), primarily involving the lungs, bones and joints, serous cavities, and lymph nodes. Common symptoms included cough/sputum production, fatigue/weight loss, fever, bone pain, and subcutaneous abscesses/skin ulcers. All patients tested positive for Mycobacterium colombiense via tNGS, while 19 cases were concurrently confirmed through culture of sputum or bronchoalveolar lavage fluid as part of the Mycobacterium avium complex. All patients received combined anti-nontuberculous mycobacterial therapy. Drug susceptibility testing performed in 11 cases revealed high sensitivity to bedaquiline, clofazimine, rifabutin, ethambutol, and rifampin.
Conclusion: Mycobacterium colombiense infection is prone to causing disseminated disease, affecting multiple organ systems with diverse clinical presentations. Timely therapeutic intervention can improve patient prognosis to some extent. This study offers valuable references for the clinical diagnosis and treatment of Mycobacterium colombiense infection, underscoring its practical significance in clinical practice.
Keywords: Mycobacterium colombiense, disseminated infection, drug susceptibility testing, nontuberculous mycobacteria, clinical characteristics
1Guangzhou Chest Hospital, Guangzhou, People’s Republic of China; 2Department of Tuberculosis, Anhui Chest Hospital, Hefei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hua Chen, Guangzhou Chest Hospital, No. 62 Hengzhigang Road, Guangzhou, People’s Republic of China, Tel +86-13570550192, Fax +86- 02083595977, Email chenhua1805@163.com
Purpose: Mycobacterium colombiense, a rare yet clinically significant species within the Mycobacterium avium complex, demonstrates a marked propensity for disseminated disease and is associated with high mortality. However, data on its clinical characteristics and drug resistance profiles remain scarce. This study aims to conduct an in-depth analysis of the clinical characteristics and drug resistance profile of Mycobacterium colombiense disease, providing insights for optimizing its diagnosis and treatment strategies.
Patients and Methods: We retrospectively analyzed the clinical data of 22 HIV-negative patients diagnosed with Mycobacterium colombiense disease at Guangzhou Chest Hospital from April 2021 to April 2024. Data included clinical manifestations, laboratory findings, and treatment regimens.
Results: Among the 22 confirmed cases, disseminated Mycobacterium colombiense disease accounted for 63.6% (14/22), primarily involving the lungs, bones and joints, serous cavities, and lymph nodes. Common symptoms included cough/sputum production, fatigue/weight loss, fever, bone pain, and subcutaneous abscesses/skin ulcers. All patients tested positive for Mycobacterium colombiense via tNGS, while 19 cases were concurrently confirmed through culture of sputum or bronchoalveolar lavage fluid as part of the Mycobacterium avium complex. All patients received combined anti-nontuberculous mycobacterial therapy. Drug susceptibility testing performed in 11 cases revealed high sensitivity to bedaquiline, clofazimine, rifabutin, ethambutol, and rifampin.
Conclusion: Mycobacterium colombiense infection is prone to causing disseminated disease, affecting multiple organ systems with diverse clinical presentations. Timely therapeutic intervention can improve patient prognosis to some extent. This study offers valuable references for the clinical diagnosis and treatment of Mycobacterium colombiense infection, underscoring its practical significance in clinical practice.
Keywords: Mycobacterium colombiense, disseminated infection, drug susceptibility testing, nontuberculous mycobacteria, clinical characteristics